News

News Subscription

Jan 23. 2020
Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASCO Gastrointestinal Cancers Symposium
Read more
Download
Jan 22. 2020
Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer
Read more
Download
Jan 10. 2020
Basilea reports total revenue exceeding guidance driven by higher than expected contributions from Cresemba® and Zevtera® in 2019
Read more
Download
Jan 08. 2020
Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progress in Cresemba commercialization and R&D portfolio in 2019
Read more
Download
Dec 16. 2019
Basilea plans progression of oncology candidate lisavanbulin to targeted, biomarker-driven phase 2 study
Read more
Download
Dec 06. 2019
Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this year from Pfizer to Basilea of USD 7 million
Read more
Download
Oct 30. 2019
Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference
Read more
Download
Oct 29. 2019
Basilea reports marketing authorization of antifungal Cresemba® in Brazil
Read more
Download
Sep 30. 2019
Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations
Read more
Download
Aug 27. 2019
Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer
Read more
Download